{"denoms":[{"counts":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"176"}],"units":"Participants"}],"groups":[{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 15-minute infusion time, but increasing to a 30-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12 weeks.","id":"BG000","title":"15 - Minute Infusion"},{"description":"Participants received 4 mg zoledronic acid intravenously, in 250 mL of fluid, every 3-4 weeks for up to 24 months, over a 30-minute infusion time, but increasing to a 45-minute infusion time if they experienced a clinically relevant rise in serum creatinine that resolved in less than 12-weeks.","id":"BG001","title":"30 - Minute Infusion"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"86"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"90"}],"title":">=65 years"}]}],"description":"Demographic data is provided for the entire Safety Population.","paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.95","value":"64.3"},{"groupId":"BG001","spread":"11.54","value":"64.0"},{"groupId":"BG002","spread":"11.7","value":"64.1"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"71"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"105"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"139"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"22"}]}],"title":"Black"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"88"},{"groupId":"BG002","value":"176"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"24.3","value":"12.5"},{"groupId":"BG001","spread":"14.1","value":"9.7"},{"groupId":"BG002","spread":"19.8","value":"11.1"}]}]}],"description":"This baseline measurement was based on n=86, 87.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Time since diagnosis","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"32.6","value":"87.3"},{"groupId":"BG001","spread":"39.5","value":"89.3"},{"groupId":"BG002","spread":"36.1","value":"88.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Calculated creatinine clearance","unitOfMeasure":"mL/min"}]}